Skip to main content
main-content

01.12.2012 | Research | Ausgabe 1/2012 Open Access

World Journal of Surgical Oncology 1/2012

Sorafenib for hepatocellular carcinoma patients beyond Milan criteria after orthotopic liver transplantation: a case control study

Zeitschrift:
World Journal of Surgical Oncology > Ausgabe 1/2012
Autoren:
Chieh-Lin Teng, Wen-Li Hwang, Yi-Ju Chen, Kuang-Hsi Chang, Shao-Bin Cheng
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​1477-7819-10-41) contains supplementary material, which is available to authorized users.

Authors' contributions

Chieh-Lin Teng participated in the writing of the paper and research design.
Wen-Li Hwang participated in the performance of the research.
Yi-Ju Chen participated in the performance of the research.
Kuang-Hsi Chang participated in data analysis.
Shao-Bin Cheng (corrsponding author) participated in the writing of the paper and research design.
All authors read and approved the final manuscript.

Abstract

Background

Orthotopic liver transplantation (OLT) is one of the most effective treatments for patients with hepatocellular carcinoma (HCC) within the Milan criteria. However, for patients beyond these criteria, the recurrence rate is higher and the prognosis is worse. Sorafenib is the only drug showing survival benefits in advanced HCC patients; however, its role in patients beyond the Milan criteria after OLT remains unclear and requires further investigation.

Methods

As a case-control study, we retrospectively analyzed 17 Chinese patients beyond Milan criteria undergoing OLT for HCC. These patients were stratified into adjuvant (n = 5), palliative (n = 6), and control groups (n = 6).

Results

Nine of 11 patients who received sorafenib after OLT needed dose reduction due to more than grade 2 side effects. The disease-free survival rates for patients with or without adjuvant sorafenib were 100% versus 37.5% (p = 0.034) at 6 months, 66.7% versus 9.4% (p = 0.026) at 12 months, and 66.7% versus 0.0% (p = 0.011) at 18 months, respectively. The overall survival rates for patients in palliative and control groups were 66.7% versus 40.0% (p = 0.248) at 6 months, 66.7% versus 40.0% (p = 0.248) at 12 months, and 50.0% versus 20.0% (p = 0.17) at 18 months, respectively. Patients in the adjuvant group had better overall survival rates than those in the palliative and control groups (p = 0.031) at 24-month follow-up.

Conclusions

Adjuvant sorafenib could possibly extend both disease-free and overall survival for HCC patients beyond Milan criteria after OLT.
Zusatzmaterial
Authors’ original file for figure 1
12957_2011_988_MOESM1_ESM.pdf
Authors’ original file for figure 2
12957_2011_988_MOESM2_ESM.pdf
Authors’ original file for figure 3
12957_2011_988_MOESM3_ESM.pdf
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2012

World Journal of Surgical Oncology 1/2012 Zur Ausgabe

Neu im Fachgebiet Chirurgie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Chirurgie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise